Shawn Tomasello

Non-Executive Director / Mesoblast

Shawn Tomasello has over 30 years of experience in the pharmaceutical and biotech industries, as well as commercial and transactional experience.

Since 2015, Ms Tomasello has been the chief commercial officer of immuno-oncology cell therapy company Kite Pharma where she played a pivotal role in the company's acquisition in 2017 by Gilead Sciences for $11.9 billion. Prior to that, she was chief commercial officer of Pharmacyclics Inc which was acquired in 2015 by AbbVie for $21 billion.

Ms Tomasello was also president of the Americas, Hematology and Oncology at Celgene Corporation where she managed over $4 billion in product revenues, and was involved in various expansion and acquisition strategies.

Lists and Charts

Roles

2018

Non-Executive Director

Mesoblast

Year started and most recent title

Total Shareholder Return as at 02/12/24

Rank	Company	1 Yr	5 Yr
16^th	Bellavista Resources	400.15%	0%
17^th	Nyrada Inc	399.89%	0%
18^th	Mesoblast	360.92%	0.62%
19^th	Petratherm	360.61%	40.77%
20^th	Chilwa Minerals	357.87%	0%

View Full List

1767 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

Person Activity

	REMUNERATION UPDATE: Non-Executive Director, Mesoblast	13 Nov 2020
	NEW ROLE: Non-Executive Director, Mesoblast	03 Nov 2020

Related Information

Access to our data for Shawn Tomasello is only available to paid subscribers with Data & Insights access.

Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.

Shawn Tomasello is linked to 1 organisation which is included in 1 list - Public Companies - non WA.

To see the data you will need to Subscribe.